ABIOMED, Inc. (ABMD) Holdings Increased by Russell Investments Group Ltd.

Russell Investments Group Ltd. grew its stake in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 1.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 49,497 shares of the medical equipment provider’s stock after buying an additional 842 shares during the quarter. Russell Investments Group Ltd. owned about 0.11% of ABIOMED worth $8,345,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently added to or reduced their stakes in the business. Allen Investment Management LLC raised its position in shares of ABIOMED by 40.6% during the 3rd quarter. Allen Investment Management LLC now owns 21,894 shares of the medical equipment provider’s stock worth $3,691,000 after buying an additional 6,320 shares in the last quarter. Sigma Planning Corp bought a new stake in shares of ABIOMED during the 3rd quarter worth about $206,000. Rhumbline Advisers raised its holdings in shares of ABIOMED by 12.5% in the 3rd quarter. Rhumbline Advisers now owns 104,316 shares of the medical equipment provider’s stock worth $17,588,000 after purchasing an additional 11,571 shares in the last quarter. Dorsey Wright & Associates bought a new stake in shares of ABIOMED in the 3rd quarter worth approximately $4,682,000. Finally, New York State Common Retirement Fund raised its holdings in shares of ABIOMED by 1.9% in the 3rd quarter. New York State Common Retirement Fund now owns 313,590 shares of the medical equipment provider’s stock worth $52,871,000 after purchasing an additional 5,719 shares in the last quarter. Institutional investors own 90.75% of the company’s stock.

In other news, VP Michael G. Howley sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $178.64, for a total transaction of $1,786,400.00. Following the sale, the vice president now owns 56,757 shares in the company, valued at $10,139,070.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Dorothy E. Puhy sold 6,364 shares of the business’s stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $179.08, for a total transaction of $1,139,665.12. Following the sale, the director now owns 39,532 shares in the company, valued at approximately $7,079,390.56. The disclosure for this sale can be found here. Insiders have sold 27,646 shares of company stock worth $4,836,333 in the last 90 days. 7.00% of the stock is owned by company insiders.

Shares of ABIOMED, Inc. (ABMD) opened at $187.00 on Thursday. ABIOMED, Inc. has a 1-year low of $103.53 and a 1-year high of $200.28. The company has a current ratio of 5.84, a quick ratio of 5.20 and a debt-to-equity ratio of 0.02. The stock has a market cap of $8,310.00, a P/E ratio of 121.52, a PEG ratio of 2.52 and a beta of 0.15.

ABIOMED (NASDAQ:ABMD) last released its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.54 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.38 by $0.16. ABIOMED had a net margin of 18.27% and a return on equity of 13.89%. The business had revenue of $132.80 million for the quarter, compared to analyst estimates of $131.18 million. During the same quarter in the previous year, the business earned $0.20 earnings per share. The firm’s revenue was up 28.9% compared to the same quarter last year. analysts forecast that ABIOMED, Inc. will post 2.38 EPS for the current fiscal year.

ABMD has been the topic of a number of research reports. Zacks Investment Research upgraded shares of ABIOMED from a “sell” rating to a “buy” rating and set a $203.00 target price on the stock in a report on Monday, October 30th. BidaskClub downgraded shares of ABIOMED from a “buy” rating to a “hold” rating in a report on Saturday, August 26th. SunTrust Banks reiterated a “buy” rating and issued a $195.00 target price on shares of ABIOMED in a report on Wednesday, November 1st. Piper Jaffray Companies reiterated a “buy” rating and issued a $160.00 target price on shares of ABIOMED in a report on Tuesday, August 29th. Finally, Jefferies Group boosted their target price on shares of ABIOMED from $175.00 to $208.00 and gave the stock a “buy” rating in a report on Friday, September 29th. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. ABIOMED currently has an average rating of “Buy” and a consensus price target of $190.43.

COPYRIGHT VIOLATION NOTICE: “ABIOMED, Inc. (ABMD) Holdings Increased by Russell Investments Group Ltd.” was originally posted by Stock Observer and is owned by of Stock Observer. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://www.thestockobserver.com/2017/12/07/abiomed-inc-abmd-holdings-increased-by-russell-investments-group-ltd.html.

ABIOMED Profile

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply